Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC

Cancer Immunology, Immunotherapy

Volumn 62, Issue 12, 2013, Pages 1841-1849

  Collins, Shauna M ^a   Bakan, Courtney E ^b   Swartzel, Gina D ^c   Hofmeister, Craig C ^a,b   Efebera, Yvonne A ^a,b   Kwon, Hakju ^d   Starling, Gary C ^e   Ciarlariello, David ^b   Bhaskar, Shakthi ^c   Briercheck, Edward L ^b   Hughes, Tiffany ^b   Yu, Jianhua ^a,b   Rice, Audie ^d   Benson, Don M ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d ABBVIE INC   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Elotuzumab; Immunotherapy; Multiple myeloma; Natural killer cells

Indexed keywords

CD16 ANTIGEN; CD69 ANTIGEN; CS1 PROTEIN; EAT 2 PROTEIN; ELOTUZUMAB; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MYELOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84890429971     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1493-8     Document Type: Article

References (26)

1. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033-1040
2. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC (2011) Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 154:745-754
3. Tai Y-T, Dillon M, Song W et al (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329-1337
4. Hsi ED, Steinle R, Balasa B et al (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775-2784
5. Stark S, Watzl C (2006) 2B4 (CD244), NTB-A, and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol 18:241-247
6. Cruz-Munoz M-E, Dong Z, Shi X, Zhang S, Veillette A (2009) Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol 10:297-305
7. Tassi I, Colonna M (2005) The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3 K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol 175:7996-8002
8. Benson DM Jr, Bakan CE, Mishra A et al (2010) The PD-1/PD-L1 signaling axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116:2286-2294
9. Zonder JA, Mohrbacher AF, Singhal S et al (2012) A Phase I multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:552-559
10. Jakubowiak AJ, Benson DM, Bensinger W et al (2012) Phase I trial of anti-CS1 antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 30:1960-1965
11. Lonial S, Vig R, Harousseau JL et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953-1959
12. Shafer-Weaver KA, Sayers T, Kuhns DB et al (2004) Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Trans Med 2:31-36
13. Benson DM Jr, Bakan CE, Zhang S et al (2011) IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118:6387-6391
14. Trotta R, Puorro KA, Paroli M et al (1998) Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol 161:6648-6656
15. Benson DM Jr, Yu J, Becknell B et al (2009) Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood 113:2706-2714
16. Fehniger TA, Shah MH, Turner MJ et al (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162:4511-4520
17. Freud AG, Yokohama A, Becknell B et al (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203:1033-1043
18. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer cell subsets. Trends Immunol 22:633-640
19. Cao E (2006) NTB-A receptor crystal structure: insights into homophilic interactions in the signaling lymphocytic activation molecule receptor family. Immunity 25:559-570
20. Kondadasula SV, Varker K, Lesinski GB et al (2008) Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow cytometric assay. Cancer Immunol Immunother 57:1137-1149
21. Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216
22. Shi J, Tricot G, Garg TK et al (2008) Bortezomib down-regulates the cell surface expression of HLA-class I and enhances natural killer cell mediated lysis of myeloma. Blood 111:1309-1317
23. Neyer L, Ding H, Chen D et al (2010) Effect of elotuzumab on circulating lymphocytes, chemokines and cytokines in multiple myeloma patients. Blood 116:4070a
24. Balasa B, Huseni M, Cherukuri J et al (2008) Elotuzumab (HuLuc63) activates CD56dim natural killer cells and monocytes resulting in the release of IP-10 and MCP-1. Blood 112:108a
25. Rice AG, Dillon MBC, Van Abbema AM, Afar DEH (2007) HuLuc63 in combination regimens with conventional and targeted therapies has additive and synergistic anti-tumor activity in pre-clinical models of myeloma. Blood 110:2517a
26. Balasa B, Yun R, Belmar N, Starling G, Rice A (2012) Natural killer (NK) cell activation, cytokine production and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (len). J Clin Oncol 30:8087a